Tesaro (TSRO) Faces Near-Term Risks to Key Drug - Report
Tweet
Share
E-mailGet Alerts TSRO Hot Sheet
Join SI Premium – FREE
Tesaro Inc. (NASDAQ: TSRO) was the target of a negative blog post at SeekingAlpha Monday. Author Richard Pearson said while enthusiasm has built for still far-off cancer drug Niraparib, the risk for the company's lead drug Rolapitant is surging.
Pearson said by the time Rolapitant even comes to market in 2015, Merck's (NYSE: MRK) Emend will already be marketed as a generic drug. Another problem for Rolapitant - which Pearson said is more severe - is that Swiss company Helsinn recently completed phase III trials of its own CINV, Netupitant, which actually combines the action of an NK-1 and a 5-HT3. Analysts have largely ignored the market potential for Netupitant but trial results are widely expected to be positive and could be announced at or before the May ASCO meeting.
Near-term challenges to Rolapitant could see the shares drop back below $21 in the coming weeks, Pearson said.
Shares of TSRO are down 1 percent early Monday to $29.10.
Link to SA Article
Pearson said by the time Rolapitant even comes to market in 2015, Merck's (NYSE: MRK) Emend will already be marketed as a generic drug. Another problem for Rolapitant - which Pearson said is more severe - is that Swiss company Helsinn recently completed phase III trials of its own CINV, Netupitant, which actually combines the action of an NK-1 and a 5-HT3. Analysts have largely ignored the market potential for Netupitant but trial results are widely expected to be positive and could be announced at or before the May ASCO meeting.
Near-term challenges to Rolapitant could see the shares drop back below $21 in the coming weeks, Pearson said.
Shares of TSRO are down 1 percent early Monday to $29.10.
Link to SA Article
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Yemen's Houthis say they launched attack on Saudi vessel with ballistic missiles
- GrubHub confidentially files for U.S. IPO
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
